United States Patent [19]

York

[11] **Patent Number: 5,008,102**

[45] **Date of Patent: Apr. 16, 1991**

[54] **BIOCOMPATIBLE INTRAOCULAR LIGHT-SCREENING COMPOSITIONS AND METHODS OF INTRAOCULAR LIGHT SCREENING**

[76] Inventor: **Kenneth K. York,** 2300 N. Edgemont, Los Angeles, Calif. 90027

[21] Appl. No.: **137,247**

[22] Filed: **Dec. 23, 1987**

Related U.S. Application Data

[63] Continuation-in-part of Ser. No. 833,896, Feb. 26, 1986, abandoned.

[51] **Int. Cl.**[5] **A61K 7/40;** A61K 7/42

[52] **U.S. Cl.** ..... **424/59;** 351/161; 351/162; 351/163; 351/160 R; 351/160 H; 427/2; 514/912; 514/149; 623/6

[58] **Field of Search** 514/912, 914; 351/160, 351/161, 162, 163; 623/6; 427/2, 59

[56] **References Cited**

U.S. PATENT DOCUMENTS

3,516,720	6/1970	Mauer	351/163
4,264,493	4/1981	Battista	351/161
4,328,803	5/1982	Pape	128/276
4,486,440	12/1984	Emanuel et al.	514/912
4,576,453	3/1986	Borowsky	351/162
4,636,212	1/1987	Posin et al.	351/162
4,657,363	4/1987	Neefe	351/162
4,669,834	6/1987	Richter	351/162
4,681,412	7/1987	Lemelson	351/162

FOREIGN PATENT DOCUMENTS

272524	7/1969	Austria	424/60
675784	12/1963	Canada	424/60
707525	4/1932	France	424/59
2073437	1/1971	France	514/912
2315949	1/1977	France	514/912
8602548	5/1986	PCT Int'l Appl.	514/912

OTHER PUBLICATIONS

Nuritdinor, Chem. Abs., 1981, vol. 94, p. 52832h.
Nutridinov (I), Chem. Abs., 1981, vol. 95, p. 49335p.
Emsley, The Optician, vol. 137, 6/1959, pp. 543–548.
"Antara" brochure, 1962, GAF Corp.,
"Polyacrylamide as a Basis for Medicinal Eye Films," by V. A. Nuritdinov, *Chem. Abstracts,* vol. 94, No. 8, 2/23/81, p. 364.
"Ultraviolet–Absorbing Chromophores . . . ", by H. M. Clayman, *Pharmaceuticals,* vol. 105, Nov. 20, 11/17/87, p. 377.

Primary Examiner—Dale R. Ore

[57] **ABSTRACT**

Temporary, light-absorbing, ocularly biocompatible compositions include at least one biocompatible, light-absorbing substance in an amount sufficient to block substantially all light of desired wavelengths and protect susceptible ocular tissues from light induced damage, where the composition is placed introcularly between the light source and ocular tissues susceptible to damage from such light. These compositions can be used to coat or to impregnate intraocular lenses, either before or after insertion of the lenses into the eye, or can be placed intraocularly, in the anterior chamber, over the pupil, in the posterior chamber or in the capsular bag of an eye, as during an ophthalmic procedure. Where the composition includes a viscous, biocompatible, space-maintaining substance such as sodium hyaluronate, chondroitin sulfate, methylcellulose or polyacrylamide, the composition also protects the endothelium, maintains space within the eye, moves tissues, allows focal application of the light-absorbing substance, and permits rapid reversal or pupillary occlusion.

10 Claims, No Drawings